Menopur (Menotrophin)

Menotrophin contains both follicle‑stimulating hormone (FSH) and luteinising hormone (LH). FSH stimulates granulosa cells to promote follicle growth and estrogen production, while LH acts on theca cells to produce androgens that are converted to estrogen. The combined hormonal activity supports follicular maturation and ovulation.

The dose of Menopur is individualized. A qualified prescriber determines the amount and frequency based on the patient’s ovarian response, underlying condition, and treatment protocol. No fixed regimen is provided in public information; dosing is adjusted during therapy under medical supervision.

Menopur is not intended for use during an established pregnancy and should be discontinued once pregnancy is confirmed. Safety data for breastfeeding are limited, and the drug is generally not recommended for nursing mothers unless the benefit outweighs potential risk, as decided by the treating physician.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and assists with import documentation.

Menopur provides both FSH and LH activity in a single preparation, whereas many recombinant products contain only FSH. This dual activity can be advantageous for patients who require LH supplementation, such as those with hypogonadotropic hypogonadism. However, recombinant FSH may offer more precise dosing and lower risk of immunogenicity. Choice depends on clinical indication, patient response and physician preference.

Menopur must be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and do not freeze or shake the solution. If the product reaches room temperature for a short period during administration, it may be used, but it should be returned to refrigeration promptly.

Menopur is supplied as a sterile injectable solution for subcutaneous injection. The vial is typically reconstituted with the diluent provided, mixed gently, and administered into the subcutaneous tissue of the abdomen or thigh using a sterile needle. Injection technique and site rotation are important to minimise local reactions.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain, shortness of breath and electrolyte disturbances, and thromboembolic events such as deep‑vein thrombosis. Rarely, anaphylactic reactions may occur. Patients should be monitored closely for these complications, especially during the first treatment cycles.

Menopur is contraindicated in women with ovarian cysts, estrogen‑dependent neoplasms, uncontrolled thyroid disease, severe liver dysfunction, or those who are pregnant. It should also be avoided in patients with known hypersensitivity to menotrophin or any component of the formulation.